What impact did TRIKAFTA have on Vertex's revenue in 2024?

TRIKAFTA had a significant impact on Vertex's revenue in 2024. The drug's continued strong performance was a primary driver of Vertex's revenue growth throughout the year. Here are the key points to consider: 1. **Revenue Growth**: TRIKAFTA's sales were instrumental in Vertex's revenue increase. In the third quarter of 2024, TRIKAFTA generated sales worth $2.48 billion, which represented an 18.5% year-over-year increase. This growth was not only significant on its own but also contributed to the overall revenue growth of the company. 2. **Full-Year Revenue Guidance**: Vertex raised its full-year product revenue guidance to $10.8 billion to $10.9 billion, primarily due to the expected continued strong performance of TRIKAFTA. This guidance indicated confidence in the drug's ability to drive revenue throughout the year. 3. **Regional Sales Dynamics**: TRIKAFTA's sales in the U.S. and ex-U.S. markets both saw significant increases. In the U.S., CF product sales rose 8% year-over-year to $1.52 billion, while sales outside the U.S. increased by 21% to $1.17 billion. This broad-based growth reinforced TRIKAFTA's role as a key revenue generator for Vertex. 4. **Pipeline and Strategic Initiatives**: Vertex's strategic focus on expanding its CF portfolio and preparing for the potential launch of new products, such as the vanzacaftor triple, further underscored the importance of TRIKAFTA in shaping the company's revenue trajectory. In summary, TRIKAFTA's robust sales performance and the associated regional and market segment growth significantly contributed to Vertex's revenue in 2024. The drug's impact was so substantial that it influenced Vertex's full-year revenue guidance, indicating a strong belief in its continued success.